Table 2

The prevalence of revealed symptoms and the reason for stopping the ETT during follow-up in the total study population

ETT1
(n=316)
ETT2
(n=170)
ETT3
(n=106)
ETT4
(n=67)
ETT final
(n=42)
Adverse events, %00000
Revealed symptoms, %2923221852
 Moderate AS, %2319201355
 Severe AS, %3829292725
Reasons for stopping ETT
 Fatigue, %4351635240
 Breathlessness, %2523162220
 Dyspnoea and fatigue, %1198920
 Chest pain, %789813
 ST segment depression, %10004
 Dizziness, %33200
 Blood pressure fall, %22232
 PVC >3, %00000
 SVT, %11110
 THR achieved, %63130
 Patient’s request, %00030
  • AS, aortic stenosis; ETT, Exercise treadmill test; PVC, premature ventricular contraction; SVT, supraventricular tachycardia; THR, target heart rate.